Q2 2026 saw 7% adjusted sales growth and a net profit of DKK 21.0 billion, driven by strong GLP-1 volume in obesity care and successful WegovyⓇ pill launches. The 2026 outlook was raised, with continued investment in R&D and significant shareholder returns.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.